Veterinary Stereotactic Radiosurgery System Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Gamma Knife, LINAC, Proton Beam Radiation Therapy (PBRT)/ Flash-RT, CyberKnife), By Application (Brain Tumours, Spinal Tumours, Other Applications), By End User (Veterinary Hospitals, Veterinary Specialty Clinics, Research and Academic Institutions), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 3.66 Billion
CAGR (2026-2031)	10.41%
Fastest Growing Segment	Brain Tumours
Largest Market	North America
Market Size (2031)	USD 6.63 Billion

Market Overview

The Global Veterinary Stereotactic Radiosurgery System Market will grow from USD 3.66 Billion in 2025 to USD 6.63 Billion by 2031 at a 10.41% CAGR. Veterinary Stereotactic Radiosurgery (SRS) Systems are specialized medical devices designed to deliver high-dose, precisely targeted radiation to treat neoplastic tumors in companion animals while preserving surrounding healthy tissue. The global market for these systems is primarily driven by the rising prevalence of cancer in the aging pet population and the increasing trend of pet humanization, which fuels owner willingness to invest in advanced healthcare. Additionally, rapid advancements in veterinary oncology and the growing availability of referral centers are supporting adoption. According to the American Pet Products Association, in 2024, spending on veterinary care and product sales in the United States reached $39.8 billion, underscoring the substantial financial commitment owners are dedicating to animal wellness.

Despite this positive trajectory, the market faces a significant challenge due to the high capital expenditure required for acquiring and installing these complex systems. The substantial costs associated with infrastructure, ongoing maintenance, and the specialized training needed for veterinary personnel limit accessibility primarily to affluent specialty hospitals and academic institutions. This financial barrier consequently restricts the availability of radiosurgery options in smaller practices and developing regions, thereby impeding the overall expansion potential of the global market.

Key Market Drivers

The rising incidence of veterinary cancer and tumor cases is a fundamental driver propelling the Global Veterinary Stereotactic Radiosurgery System Market. As the lifespan of companion animals increases, the susceptibility to neoplastic diseases such as brain tumors, osteosarcoma, and nasal carcinomas rises, creating a critical need for high-precision, non-invasive treatment modalities. Stereotactic radiosurgery is increasingly favored for its ability to deliver ablative radiation doses to these complex targets while sparing healthy tissue, offering a viable alternative to debilitating surgeries. Underscoring this prevalence, according to the American Veterinary Medical Association (AVMA), February 2025, approximately 1 in 4 dogs will develop cancer at some point during their life, a high incidence rate that directly correlates with the growing demand for sophisticated oncology interventions.

Simultaneously, the increasing trend of pet humanization and healthcare expenditure is dismantling financial barriers to the adoption of these advanced systems. Owners are progressively viewing pets as integral family members, leading to a willingness to invest in premium medical care, a trend significantly bolstered by the expansion of the pet insurance sector. This financial capacity is quantitatively demonstrated by the industry's growth; according to the North American Pet Health Insurance Association (NAPHIA), June 2025, the total premium volume in the United States reached $4.7 billion in 2024, reflecting a 21.4% increase from the prior year. This surge in insured pets supports the infrastructure for specialized care; according to Today's Veterinary Practice, June 2025, the number of active board-certified veterinary oncologists in North America grew to 600 in 2024, facilitating the wider deployment of radiosurgery platforms.

Download Free Sample Report

Key Market Challenges

The significant capital expenditure associated with acquiring and installing Veterinary Stereotactic Radiosurgery (SRS) systems serves as a primary restraint on the expansion of the global market. These systems necessitate a massive initial financial outlay that extends beyond the purchase price of the unit to include the construction of specialized radiation-shielded vaults and the retrofitting of existing infrastructure. Furthermore, the operational budget must accommodate the high costs of ongoing maintenance and the salaries of highly specialized personnel, such as veterinary oncologists and medical physicists. This economic burden effectively limits the potential customer base to elite academic institutions and large-scale specialty referral centers, thereby excluding the vast majority of private veterinary practices from adopting this technology.

This financial barrier creates a stark disparity between the cost of advanced radiosurgery capabilities and the economic reality of typical veterinary businesses. According to the American Veterinary Medical Association (AVMA), in its 2025 Report on the Economic State of the Veterinary Profession, the average gross revenue for a U.S. veterinary practice was approximately $1.5 million in 2024. With the average annual revenue of a practice remaining at this level, the capacity for most facilities to finance radiosurgery systems, which often cost significantly more than their total annual earnings, is virtually non-existent. This lack of affordability severely restricts the total addressable market and prevents the widespread proliferation of SRS technology across the broader veterinary sector.

Key Market Trends

The Adoption of Hypofractionated Stereotactic Treatment Protocols is fundamentally reshaping the veterinary oncology landscape by shifting clinical standards from prolonged, multi-week radiation courses to high-precision, condensed regimens. This transition is primarily driven by the clinical imperative to minimize anesthesia-related risks in companion animals, as hypofractionation delivers ablative doses in as few as one to three sessions compared to traditional protocols. The rapid uptake of these advanced modalities is evident in recent clinical caseloads; according to the National Institutes of Health, November 2025, a retrospective study on veterinary radiation trends reported a 103.4% increase in the number of patients receiving radiation therapy over a four-year period, reflecting the surging clinical demand for these sophisticated, efficiency-enhancing treatment options.

Concurrently, the Proliferation of SRS Capabilities in Private Specialty Referral Centers is decentralizing advanced cancer care, moving it beyond the exclusive domain of academic teaching hospitals into widespread corporate veterinary networks. Large-scale private health groups are increasingly investing in state-of-the-art linear accelerators and board-certified talent, effectively creating a new tier of research-driven private practice that rivals university capabilities. This structural shift is quantitatively demonstrated by the academic output of these private entities; according to Mars Veterinary Health, April 2025, in its inaugural Science Impact Report, clinicians across its global network authored more than 450 peer-reviewed manuscripts in a single year, highlighting how private referral centers have become pivotal engines for clinical innovation and the expanding accessibility of radiosurgery services.

Segmental Insights

The Brain Tumours segment represents the fastest-expanding category in the Global Veterinary Stereotactic Radiosurgery System Market due to the significant challenges associated with conventional surgery in the cranial region. Veterinary oncologists increasingly adopt stereotactic radiosurgery for treating brain cancers, such as meningiomas, because it delivers precise radiation while minimizing harm to healthy brain tissue. This non-invasive method is essential for managing deep-seated tumors that are otherwise inoperable. Furthermore, improved accessibility to diagnostic imaging has heightened the detection of neurological malignancies in geriatric pets, thereby accelerating the demand for these specialized therapeutic interventions.

Regional Insights

North America holds a dominant position in the Global Veterinary Stereotactic Radiosurgery System Market, driven by a well-established veterinary healthcare infrastructure and substantial animal healthcare expenditure. The region features a dense concentration of specialty oncology centers and university teaching hospitals that readily adopt advanced therapeutic technologies. Additionally, the growing availability of pet health insurance improves the financial accessibility of complex treatments for owners. The strong local presence of medical device manufacturers, combined with clinical standards supported by the American Veterinary Medical Association, further reinforces North America’s leading status in this sector.

Recent Developments

• In December 2024, Varian Medical Systems reported on the successful implementation of its Veterinary Dosimetry Services at the Veterinary Specialty Center in Chicago. The company highlighted that this remote service streamlined treatment planning workflows for veterinary hospitals utilizing Halcyon radiotherapy systems. By integrating certified medical dosimetrists directly into the hospital’s digital workflow, the service achieved plan turnaround times of between 24 and 72 hours. This collaboration allowed the veterinary radiation oncologists to increase patient capacity and improve operational efficiency by offloading complex planning tasks to Varian’s specialized team, ensuring high-quality, consistent care for animal patients.
• In September 2024, BluePearl Pet Hospital in Malvern, Pennsylvania, announced the inauguration of the world's only CyberKnife Center dedicated solely to veterinary medicine. The facility adopted the Accuray CyberKnife robotic radiotherapy system to provide non-invasive treatment for cancerous and non-cancerous tumors in companion animals. The Radiation Oncologist at the hospital emphasized that the technology’s sub-millimeter precision and real-time motion synchronization allowed for the safe treatment of surgically complex or inoperable tumors. This launch represented a significant expansion of advanced oncology options available to pet owners, offering a pain-free alternative with no required recovery time.
• In April 2024, PetCure Oncology, in partnership with Thrive Pet Healthcare, announced a major milestone of administering stereotactic radiation therapy (SRS) to over 8,000 pets since its inception. The organizations highlighted that the majority of these cases benefited from the advanced SRS modality, which delivers high doses of radiation in fewer sessions compared to traditional veterinary radiotherapy. The Medical Director for PetCure Oncology noted that this technology had transformed the landscape of veterinary cancer care by significantly reducing anesthetic events and enabling the effective treatment of previously untreatable cancers in sensitive areas such as the liver, spine, and lungs.
• In February 2024, the University of Glasgow's Small Animal Hospital announced a significant investment of £1.7million in a new Varian VitalBeam linear accelerator. Facilitated by a legacy donation, this acquisition marked a major upgrade for their referral oncology service and integrated neuro-oncology centre. The new system was designed to deliver cutting-edge treatments with high precision, ensuring that normal tissue surrounding tumours is spared during procedures. This capability is particularly critical for treating complex brain and spinal cord tumours. The hospital stated that this state-of-the-art facility would play a key role in training future veterinary students while enhancing patient outcomes across the region.

Key Market Players

• Avante Health Solutions LLC
• Accuray Inc.
• Elekta AB
• Varian Medical Systems Inc.
• PetCure Oncology LLC
• Xstrahl Inc.
• CVS Group
• Medtronic PLC
• Nanovi AS
• Merck & Co. Inc.

By Product	By Application	By End User	By Region
Gamma Knife LINAC Proton Beam Radiation Therapy (PBRT)/ Flash-RT CyberKnife	Brain Tumours Spinal Tumours Other Applications	Veterinary Hospitals Veterinary Specialty Clinics Research Academic Institutions	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Veterinary Stereotactic Radiosurgery System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Stereotactic Radiosurgery System Market, By Product:

• Gamma Knife
• LINAC
• Proton Beam Radiation Therapy (PBRT)/ Flash-RT
• CyberKnife

• Veterinary Stereotactic Radiosurgery System Market, By Application:

• Brain Tumours
• Spinal Tumours
• Other Applications

• Veterinary Stereotactic Radiosurgery System Market, By End User:

• Veterinary Hospitals
• Veterinary Specialty Clinics
• Research
• Academic Institutions

• Veterinary Stereotactic Radiosurgery System Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE